This site is intended for Healthcare Professionals only.

NICE recommends Forxiga to treat chronic kidney disease

Date:

Share post:

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD).

Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.

Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system.

“Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse,” Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

“Our independent appraisal committee heard from people with the disease who said that further options which prevented the progress of the disease would offer real hope and a much-improved quality of life. Alongside standard care, dapagliflozin has the potential to significantly reduce the risk of end-stage kidney disease.”

It is estimated that there are around 91,000 people who could be eligible for this treatment in England.

CKD is a long-term condition in which the kidneys do not work as well as they should and is common, especially in older people. It is often caused by other conditions that affect the kidneys, including diabetes, high blood pressure, high cholesterol and kidney infections.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

#SaveOurPharmacies: NPA distributes fair funding campaign posters, stickers

The National Pharmacy Association (NPA) is distributing new campaign materials to pharmacies across England this week to empower...

Lake District pharmacy grapples with medicine shortages amidst growing crisis

79% of pharmacists fear for patient health according to Community Pharmacy England report A Lake District pharmacy is grappling...

Common antibiotic for whooping cough treatment ‘completely out of stock’ – Dr. Leyla Hannbeck

Whooping cough caused five infant deaths in the first quarter of 2024, according to UKHSA Pharmacists in the UK...

Labour with Nuffield Health to aid thousands of NHS staff with joint pain return to work

Nurses accounted for 52,000 of sick days, doctors for 3,500, both up since 2019 as per the Labour...